Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 2Thoracic 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 27Ovarian Neoplasms 14Lung Neoplasms 12Melanoma 11Colorectal Neoplasms 9Breast Neoplasms 9Stomach Neoplasms 7Pancreatic Neoplasms 7Triple Negative Breast Neoplasms 6Neoplasms 6Neoplasm Metastasis 6Mesothelioma 6Carcinoma, Merkel Cell 5Small Cell Lung Carcinoma 4Multiple Myeloma 4Mesothelioma, Malignant 4Head and Neck Neoplasms 4Esophageal Neoplasms 4Carcinoma, Transitional Cell 4Carcinoma, Renal Cell 4Carcinoma, Hepatocellular 4Uterine Cervical Neoplasms 3Urogenital Neoplasms 3Urinary Bladder Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Recurrence 3Liver Neoplasms 3Cholangiocarcinoma 3Carcinoma, Squamous Cell 3Thymoma 2

Interventions

fludarabine phosphate 1fludarabine 1entinostat 1carboxyamido-triazole 1aldesleukin 1Thalidomide 1Paclitaxel 1Fentanyl 1Docetaxel 1Cyclophosphamide 190Y-octreotide, DOTA-Tyr(3)- 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Meningioma × fludarabine × Thoracic × Clear all
NCT01967823 2021-03-24

T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
11 enrolled 12 charts
BreastCNSDermatologicGastrointestinalThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Liver Neoplasms, Melanoma, Meningioma, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡